Clinical trials: SLE; Drug
Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B cell mediated autoimmune disease.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
- Trial name
- NCT07305116
- Testing
- UCAR T-cell
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Systemic Lupus Erythematosus, Rheumatoid Arthritis
A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases
The purpose of this study is to learn about the safety and effects of the study medication called PF-08154225 for the potential treatment of autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Idiopathic Inflammatory Myositis, Systemic Sclerosis
- Trial name
- NCT07782450
- Testing
- PF-08154225
- Volunteers
- 54 people
- Sponsor
- Pfizer
Systemic Lupus Erythematosus, Medication Adherence
Effectiveness of Pharmaceutical Care in the Adherence of Systemic Lupus Erythematosus Treatment
This project aims to improve adherence rate through pharmaceutical care in patients with systemic lupus erythematosus (SLE) to help achieving therapeutic goals and finally to improve the quality of life of these patients.
- Trial name
- ADELES (NCT02330250)
- Testing
- Pharmaceutical Care, Control
- Where
- Brazil
- Volunteers
- 131 people
- Sponsor
- Oswaldo Cruz Foundation
Systemic Lupus Erythematosus
Intervention to Improve Communication and Medication Adherence in Lupus
CO-LEAD is an intervention to improve patient-provider communication and medication adherence among patients with systemic lupus erythematosus (SLE).
- Trial name
- CO-LEAD (NCT06458075)
- Testing
- CO-LEAD
- Where
- United States
- Volunteers
- 480 people
- Sponsor
- Duke University
Systemic Lupus Erythematosus
A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE)
This study is an open-label, single-arm, dose escalation and dose expansion study to evaluate the safety, maximum tolerated dose, pharmacokinetic characteristics of allogeneic CD19-CAR-DNT cells (RJMty19) after infusion, and…
- Trial name
- NCT06340490
- Testing
- RJMty19 (CD19-CAR-DNT cells)
- Where
- 4 sites in China
- Volunteers
- 24 people
- Sponsor
- Guangdong Ruishun Biotech Co., Ltd
Lupus Nephritis, SLE Nephritis
The Effect of Curcumin on the Clinical Outcome of Pediatric Patients with Active Lupus Nephritis
Pediatric Lupus nephritis which is a sever and common complication to childhood onset systemic lupus erythematous is an aggressive inflammatory process triggered by the deposition of antigen-antibody complex in kidney tissue.
- Trial name
- NCT05714670
- Testing
- Curcumin Oral Capsule
- Where
- Egypt
- Volunteers
- 72 people
- Sponsor
- Ain Shams University
Systemic Lupus Erythematosus
The Safety and Efficacy of Zishenqing in Subjects With Active Systemic Lupus Erythematosus
This study evaluates the safety and efficacy of the traditional chinese medicine Zishenqing in the treatment of active systemic lupus erythematosus.
- Trial name
- NCT04275193
- Testing
- Zishenqing
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases
The goal of this clinical trial is to evaluate CLBR001 and SWI019 as a treatment for patients with autoimmune disorders, including systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myositis.
- Conditions
- Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)
- Trial name
- NCT06913608
- Testing
- CLBR001 + SWI019
- Sponsor
- Calibr, a division of Scripps Research
Autoimmune Diseases, SLE - Systemic Lupus Erythematosus
RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
This is a single-arm, open-label, phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-05, a universal CD19/BCMA dual-targeting chimeric antigen receptor T-cell…
- Conditions
- Autoimmune Diseases, SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory Myopathies
- Trial name
- NCT07674147
- Testing
- RD06-05 CART Cell Infusion
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Systemic Lupus Erythematosus
Psychoeducational Approach to Improve Health in Lupus
We will study the relationships among patient/partner communication, social support, and self-efficacy (a person's belief in the ability to manage his or her disease) as they affect the health of people with systemic lupus…
- Trial name
- NCT00000417
- Testing
- Counseling intervention, Informational film
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Brigham and Women's Hospital
Rheumatic Diseases, Inflammatory Arthritis
The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions
The goal of this prospective observational quality improvement study is to determine if a physician tool, MedSafer, combined with educational brochures for patients, can help to reduce the use of 'potentially inappropriate…
- Conditions
- Rheumatic Diseases, Inflammatory Arthritis, Systemic Lupus Erthematosus (SLE), Vasculitis
- Trial name
- NCT07278609
- Testing
- MedSafer deprescribing opportunity reports, EMPOWER brochures
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Systemic Lupus Erythematosus, Lupus Nephritis
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic…
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
- Trial name
- CALiPSO-1 (NCT06255028)
- Testing
- CNTY-101, IL-2, Lymphodepleting Chemotherapy
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Century Therapeutics, Inc.
SLE; Drug
Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE
The clinical trial is titled "A Phase 1b/2a Multicenter Study to Assess the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of KPG-818 in Patients with Systemic Lupus Erythematosus".
- Trial name
- Lupus (NCT04643067)
- Testing
- KPG-818 low dose in phase 1b, KPG-818 mid dose in phase 1b, KPG-818 high dose in phase 1b
- Where
- 18 sites in United States
- Volunteers
- 64 people
- Sponsor
- Kangpu Biopharmaceuticals, Ltd.
Systemic Lupus Erythematosus, Lupus Nephritis
Therapeutic Drug Monitoring of Mycophenolate Mofetil in Lupus Nephritis
Systemic lupus erythematosus (SLE) is an inflammatory, chronic, and multisystem autoimmune disease characterized by periods of activity and remission.
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Drug Monitoring, Mycophenolic Acid
- Trial name
- LUPUS-MONITOR (NCT07493655)
- Testing
- Therapeutic Drug Monitoring, Standard clinical care
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- Federal University of Maranhao
Interstitial Lung Disease, Connective Tissue Disease
A Clinical Trial for CTD-ILD Treatment
The first objective of this protocol is to assess the tolerability and safety of N-acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung disease (CTD-ILD).
- Trial name
- NCT01424033
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan
Nephrotic Syndrome, Systemic Lupus Erythematosus
Drug Therapy in Lupus Nephropathy
Studies have shown that up to 26% of patients with systemic lupus erythematoses nephritis may suffer from membranous lupus nephropathy.
- Trial name
- NCT00001212
- Testing
- prednisone, cyclophosphamide, cyclosporin A
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Malaria
Adherence to Antimalarial Drugs in Sierra Leone
The aim of this study is to address this gap in knowledge by measuring the level of patient adherence to co-formulated amodiaquine and artesunate (AQ-AS) compared to artemether-lumefantrine (AL) under routine conditions in Sierra…
- Trial name
- NCT01967472
- Testing
- amodiaquine-artesunate (AQAS) fixed-dose, Artemether-lumefantrine combination (AL) dispersable
- Where
- 2 sites in Sierra Leone
- Volunteers
- 1,145 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Systemic Lupus Erythematosus (SLE), Immune-mediated Necrotizing Myopathy (IMNM)
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
This is an investigator-initiated, multicenter, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard…
- Conditions
- Systemic Lupus Erythematosus (SLE), Immune-mediated Necrotizing Myopathy (IMNM), Neuromyelitis Optica Spectrum Disorders (NMOSD), Multiple Sclerosis (MS)
- Trial name
- CAR-AID (NCT06249438)
- Testing
- CD20/BCMA-directed CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- RenJi Hospital